NY-ADACORE
13.6.2024 11:23:28 CEST | Business Wire | Press release
AdaCore https://www.adacore.com/ is thrilled to be part of the Safety-Critical Rust Consortium alongside The Rust Foundation, Arm, Ferrous Systems, OxidOS, Synopsys, HighTec EDV-Systeme GmbH, TrustInSoft, Veecle, and Woven by Toyota. The primary objective of this group will be to support the responsible use of the Rust programming language in safety-critical software — systems whose failure can impact human life or cause severe environmental or property harm.
Safety-Critical Rust Consortium Membership is open to Rust Foundation member organizations and other invitees, such as industry, academic, and legal experts.
Work under the consortium will begin with the creation of a public charter and goals, and meeting minutes will be published on an ongoing basis. The Safety-Critical Rust Consortium will liaise with the Rust Project through Rust Foundation Project Directors and members of Rust Project teams. The Consortium’s scope, which will be fully delineated in the charter, may include the development of guidelines, linters, libraries, static analysis tools, formal methods, and language subsets to meet industrial and legal requirements. The Consortium’s deliverables will be developed and licensed in a manner compatible with other Rust Project endeavors.
The group may further shepherd Rust Foundation-funded implementation work, including grants to existing academic teams or FOSS projects. Any Rust Foundation-funded work will be submitted upstream, licensed as FOSS, and any specifications will be freely available. The group will further attempt to coordinate with and expand on existing safety-critical projects and standards including SAE JA1020.
Programming-language safety refers to a language’s ability to prevent errors or undefined behaviors at compile time or runtime. On the other hand, "safety-critical" refers to a system’s ability to operate without causing accidents or catastrophic failures that will result in harm to people, property or the environment. So, while safety-critical systems rely on languages that emphasize safety and security, such as Rust, programming tools are only one component of the overall strategy.
Tony Aiello is the Product Manager at AdaCore,
“At AdaCore, we focus on industries where safety, security, and reliability are paramount including automotive, aviation, and space. AdaCore has decades of experience serving these industries with Ada, SPARK, and C++. Participating in the Safety-Critical Rust Consortium enables us to leverage our expertise to help the Rust community best position itself to serve the safety-critical community’s needs.”
About AdaCore
Everything we do at AdaCore is centered around helping developers build safe, secure and reliable software. With over 30 years of experience working with the most respected companies in industries such as aerospace, defense and railways, we build tools and provide services that ease the complex and often difficult process of developing high-integrity software. As the need for truly secure and reliable applications expands into industries such as automotive, medical, energy, and IoT, we’re excited to bring our time-tested technologies, expertise and services to help a whole new generation of developers.
About The Rust Foundation
The Rust Foundation is an independent nonprofit dedicated to the safety, security, sustainability, and health of the Rust Programming language and the people who use it. Through close partnerships with organizations passionate about Rust and the growing Rust Project and community, the Rust Foundation is helping forge a better open-source future with Rust.
Visit the Rust Foundation website to learn more. Follow the Rust Foundation on X (formerly known as Twitter) and on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613424332/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
